Drug Approval | July 26, 2024
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The company will also share results in two additional posters for deuruxolitinib
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
